Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat

被引:68
作者
Zamek-Gliszczynski, Maciej J.
Hoffmaster, Keith A.
Humphreys, Joan E.
Tian, Xianbin
Nezasa, Ken-ichi
Brouwer, Kim L. R.
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Pfizer Res Technol Ctr, Cambridge, MA USA
[3] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
关键词
D O I
10.1124/jpet.106.101840
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The hepatic excretion of hydrophilic conjugates, end products of phase II metabolism, is not completely understood. In the present studies, transport mechanism(s) responsible for the biliary excretion of 4-methylumbelliferyl glucuronide (4MUG) and 4-methylumbelliferyl sulfate (4MUS) were studied. Isolated perfused livers (IPLs) from Mrp2-deficient (TR-) Wistar rats were used to examine the role of Mrp2 in the biliary excretion of 4MUG and 4MUS. After a 30-mu mol dose of 4-methylumbelliferone, cumulative biliary excretion of 4MUG was extensive in wild-type rat IPLs (25 +/- 3 mu mol) but was negligible in TR- livers (0.4 +/- 0.1 mu mol); coadministration of the Bcrp and P-glyco-protein inhibitor GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5methoxy- 9-oxo-4-acridine carboxamide] had no effect on 4MUG biliary excretion in wild-type rat IPLs. In contrast, biliary excretion of 4MUS was partially maintained in Mrp2-deficient rat IPLs. Recovery of 4MUS in bile was similar to 50 to 60% lower in both control TR- (149 +/- 8 nmol) and wild-type IPLs with GF120918 coadministration (176 +/- 30 nmol) relative to wild-type control livers (378 +/- 37 nmol) and was nearly abolished in TR- IPLs in the presence of GF120918 (13 +/- 8 nmol). These changes were the result of decreased rate constants governing 4MUG and 4MUS biliary excretion. In vitro assays and perfused livers from Bcrp and P-glycoprotein gene-knockout mice indicated that 4MUS did not interact with P-glycoprotein but was transported by Bcrp in a GF120918-sensitive manner. In the rat liver, Mrp2 mediates the biliary excretion of 4MUG, whereas both Mrp2 and Bcrp contribute almost equally to the transport of 4MUS into bile.
引用
收藏
页码:459 / 467
页数:9
相关论文
共 40 条
  • [1] Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen
    Adachi, Y
    Suzuki, H
    Schinkel, AH
    Sugiyama, Y
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (03) : 923 - 928
  • [2] Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats
    Chen, C
    Hennig, GE
    Manautou, JE
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (06) : 798 - 804
  • [3] Carrier-mediated entry of 4-methylumbelliferyl sulfate: Characterization by the multiple-indicator dilution technique in perfused rat liver
    Chiba, M
    Schwab, AJ
    Goresky, CA
    Pang, KS
    [J]. HEPATOLOGY, 1998, 27 (01) : 134 - 146
  • [4] CHIBA M, 1993, J PHARMACOL EXP THER, V266, P492
  • [5] Chu XY, 1997, J PHARMACOL EXP THER, V281, P304
  • [6] Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
    de Bruin, M
    Miyake, K
    Litman, T
    Robey, R
    Bates, SE
    [J]. CANCER LETTERS, 1999, 146 (02) : 117 - 126
  • [7] FONTAINE L, 1968, Therapie (London/Paris), V23, P51
  • [8] Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
    Hirohashi, T
    Suzuki, H
    Sugiyama, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (21) : 15181 - 15185
  • [9] Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats
    Horikawa, M
    Kato, Y
    Sugiyama, Y
    [J]. PHARMACEUTICAL RESEARCH, 2002, 19 (09) : 1345 - 1353
  • [10] Bisphenol A glucuronidation and excretion in liver of pregnant and nonpregnant female rats
    Inoue, H
    Tsuruta, A
    Kudo, S
    Ishii, T
    Fukushima, Y
    Iwano, H
    Yokota, H
    Kato, S
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) : 55 - 59